Olivier Laureau

Stories

Servier spends $2.5 billion on Day One Biopharmaceuticals to lock in a rare pediatric cancer treatment

As of May 2026: Leading Servier's 2030 oncology expansion strategy

For decades, children with relapsed brain tumors had no approved targeted treatment. That changed in April 2024 when the FDA cleared Ojemda, a once-weekly pill for pediatric low-grade glioma, the most common childhood brain cancer. Day One Biopharmaceuticals, the company behind it, has agreed to be acquired by France's Servier for $2.5 billion in cash—a 68% premium over its previous closing share price.

Updated May 30

Notable Quotes

"This acquisition of Day One Biopharmaceuticals marks another decisive step in strengthening Servier's position in rare oncology. It reflects our long-term commitment to investing in science that can make a meaningful difference for patients." — Statement on Day One acquisition, March 2026

from Servier spends $2.5 billion on Day One Biopharmaceuticals to lock in a rare pediatric cancer treatment · Updated May 30